| Molecular profiling for breast cancer: a comprehensive review M Kittaneh, AJ Montero, S Glück Biomarkers in cancer 5, BIC. S9455, 2013 | 260 | 2013 |
| A phase 1b/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: Early encouraging clinical activity. JA Sosman, M Kittaneh, MPJK Lolkema, MA Postow, G Schwartz, ... Journal of Clinical Oncology 32 (15_suppl), 9009-9009, 2014 | 132 | 2014 |
| Clinical activity of AMG 337, an oral MET kinase inhibitor, in adult patients (pts) with MET-amplified gastroesophageal junction (GEJ), gastric (G), or esophageal (E) cancer. EL Kwak, P LoRusso, O Hamid, F Janku, M Kittaneh, DVT Catenacci, ... Journal of Clinical Oncology 33 (3_suppl), 1-1, 2015 | 96 | 2015 |
| Medical and surgical care of patients with mesothelioma and their relatives carrying germline BAP1 mutations M Carbone, HI Pass, G Ak, HR Alexander Jr, P Baas, F Baumann, ... Journal of Thoracic Oncology 17 (7), 873-889, 2022 | 56 | 2022 |
| Clinical and pharmacodynamic (PD) results of a phase I trial with AMP-224 (B7-DC Fc) that binds to the PD-1 receptor. PLR Jeffrey R. Infante, John D. Powderly, Howard A, SCR Institute, ... J Clin Oncol, abstr 3044, 2013 | 46 | 2013 |
| Phase I study of AMG 337, a highly selective small-molecule MET inhibitor, in patients with advanced solid tumors DS Hong, P LoRusso, O Hamid, F Janku, M Kittaneh, DVT Catenacci, ... Clinical Cancer Research 25 (8), 2403-2413, 2019 | 43 | 2019 |
| BAP1: role in carcinogenesis and clinical implications DA Kobrinski, H Yang, M Kittaneh Translational Lung Cancer Research 9 (Suppl 1), S60, 2020 | 36 | 2020 |
| Phase 1/2 study of oral rucaparib: Final phase 1 results. RS Kristeleit, HA Burris, P LoRusso, MR Patel, US Asghar, F El-Khouly, ... Journal of Clinical Oncology 32 (15_suppl), 2573-2573, 2014 | 36 | 2014 |
| Detecting germline BAP1 mutations in patients with peritoneal mesothelioma: benefits to patient and family members. M Kittaneh, C Berkelhammer J Transl Med. 2018 Jul 13;16(1):194. doi: 10.1186/s12967-018-1559-7., 2018 | 35 | 2018 |
| Current cancer treatment-novel beyond conventional approaches Ö Özdemir | 35 | 2011 |
| Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable … J Abraham, R Coleman, A Elias, FA Holmes, K Kalinsky, M Kittaneh, ... Breast cancer research and treatment 171, 11-20, 2018 | 34 | 2018 |
| First-in-human study of AMG 337, a highly selective oral inhibitor of MET, in adult patients (pts) with advanced solid tumors. DS Hong, P LoRusso, O Hamid, DM Beaupre, F Janku, R Khan, ... Journal of Clinical Oncology 32 (15_suppl), 2508-2508, 2014 | 34 | 2014 |
| Phase Ib/II study of LEE011, everolimus, and exemestane in postmenopausal women with ER+/HER2-metastatic breast cancer. A Bardia, S Modi, M Chavez-Mac Gregor, M Kittaneh, AJ Marino, ... Journal of Clinical Oncology 32 (15_suppl), 535-535, 2014 | 31 | 2014 |
| Phase I study of REGN421 (R)/SAR153192, a fully-human delta-like ligand 4 (Dll4) monoclonal antibody (mAb), in patients with advanced solid tumors. A Jimeno, P LoRusso, RM Strother, JR Diamond, L Plato, A Younger, ... Journal of Clinical Oncology 31 (15_suppl), 2502-2502, 2013 | 29 | 2013 |
| Advances in therapeutic approaches for triple-negative breast cancer R Mahtani, M Kittaneh, K Kalinsky, E Mamounas, S Badve, C Vogel, ... Clinical breast cancer 21 (5), 383-390, 2021 | 27 | 2021 |
| Exemestane in the Adjuvant Treatment of Breast Cancer in Postmenopausal Women M Kittaneh, S Glück Breast Cancer, 2011 | 26 | 2011 |
| Successful use of Trastuzumab with anthracycline-based chemotherapy followed by trastuzumab maintenance in patients with advanced HER2-positive gastric cancer S Palacio, A Loaiza-Bonilla, M Kittaneh, C Kyriakopoulos, RE Ochoa, ... Anticancer research 34 (1), 301-306, 2014 | 25 | 2014 |
| Phase Ib/II study of LEE011 (CDK4/6 inhibitor) and LGX818 (BRAF inhibitor) in BRAF-mutant melanoma M Taylor, J Sosman, R Gonzalez, MS Carlino, M Kittaneh, MP Lolkema, ... Annals of Oncology 25, iv374, 2014 | 22 | 2014 |
| Pharmacokinetics and safety of an oral ALK inhibitor, ASP3026, observed in a phase I dose escalation trial. A Patnaik, P LoRusso, HA Ball, E Bahceci, G Yuen, KP Papadopoulos, ... Journal of Clinical Oncology 31 (15_suppl), 2602-2602, 2013 | 22 | 2013 |
| Safety and pharmacokinetics of veliparib extended‐release in patients with advanced solid tumors: a phase I study TL Werner, J Sachdev, EM Swisher, M Gutierrez, M Kittaneh, MN Stein, ... Cancer Medicine 7 (6), 2360-2369, 2018 | 20 | 2018 |
Alberto J. MonteroUniversity Hospitals/Seidman Cancer Center Case Western Reserve UniversityVerified email at UHhospitals.org
